New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
08:58 EDTACORAcorda Therapeutics delays start of Phase 3 study of dalfampridine-QD to 2H
Acorda Therapeutics announced that the initiation of its Phase 3 study of dalfampridine-QD in people with post-stroke walking deficits will begin in the second half of 2014; previously the company had projected study initiation in the second quarter of 2014. The developer of the once-daily, or QD, formulation has informed the company of an alcohol dose dumping finding in vitro and the company will need to perform a short clinical study to determine whether this also exists in vivo. The clinical study will be conducted in healthy volunteers and is expected to be completed in the third quarter of 2014, Acorda said.
News For ACOR From The Last 14 Days
Check below for free stories on ACOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
06:24 EDTACORAcorda Therapeutics backs FY14 R&D $60M-$70M
Subscribe for More Information
06:24 EDTACORAcorda Therapeutics reports Q2 Ampyra revenue $87.4M
Subscribe for More Information
06:23 EDTACORAcorda Therapeutics reports Q2 GAAP EPS 11c, consensus 15c
Subscribe for More Information
July 17, 2014
11:07 EDTACORAcorda sues Mylan over plans to duplicate Ampyra MS drug, Bloomberg says

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use